Manufacturing methods for new drugs could be made greener and more efficient with the help of marine microbes.
Manufacturing methods for new drugs could be made greener and more efficient with the help of marine microbes. The project, which is being conducted by researchers at Heriot Watt University and Plymouth Marine Laboratory in collaboration with Ingenza Ltd (all UK) will use biochemical techniques to identify potentially useful enzymes in marine microbes.
"We are looking to find naturally occurring microbes that already have a built-in capacity to do the chemical reactions we want to perform in industry," Robert Speight, Operations Director at Ingenza Ltd (UK), explained in a statement. "There is every possibility of developing more efficient and sustainable manufacturing solutions for pharmaceuticals and agrochemicals in particular as a result of this search."
The team will be specifically looking for enzymes that can convert compounds which would previously have been waste products in the manufacturing process into the desired product. After finding these enzymes, the researchers will attempt to produce them in higher yield by treating the microbes under specific conditions. "The enzymes then undergo systematic testing to evaluate their activity, which enables us to pinpoint candidates that exhibit the best performance," Mark Keane, Director of Postgraduate Research, School of Engineering and Physical Sciences at Heriot-Watt University said in the statement.
The work was funded by the UK's Biotechnology and Biological Sciences Research Council (BBSRC) and the Technology Strategy Board. In the statement, Doug Kell, Chief Executive Professor of the BBSRC, said: "Green and White biotechnologies are going to be an increasingly important part of the manufacturing landscape. Looking to biological systems that have been finely tuned by evolution to solve problems, rather than starting from scratch every time, might seem an obvious thing to do. It does, however, require the bringing together of particular niche expertise."
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.